The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis
BMC Gastroenterology · 2024
DOI: 10.1186/s12876-024-03480-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift BMC Gastroenterology, 2024. Verfasst von Xinyue Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Infliximab, Remission Induction, Gastrointestinal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Sichuan Province.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China.
- Department of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, China. zhongxl519@hotmail.com.
Förderung
- National Natural Science Foundation of China
- Science and Technology Department of Sichuan Province
Zitieren
APA
Hu, X., Tang, X., Li, L., Luo, L., He, X., Yan, Q., & Zhong, X. (2024). The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis. BMC Gastroenterology. https://doi.org/10.1186/s12876-024-03480-9
Vancouver
Hu X, Tang X, Li L, Luo L, He X, Yan Q, et al. The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis. BMC Gastroenterology. 2024. doi:10.1186/s12876-024-03480-9
BibTeX
@article{Hu2024,
author = {Hu, Xinyue and Tang, Xiaowei and Li, Limin and Luo, Lian and He, Xinsen and Yan, Qin and Zhong, Xiaolin},
title = {The efficacy of CT-P13, a biosimilar of infliximab, in inflammatory bowel diseases: a systematic review and meta-analysis},
journal = {BMC Gastroenterology},
year = {2024},
doi = {10.1186/s12876-024-03480-9}
}
EUVIMED